AHA: 20 late-breaking trials, 19 special reports on docket

The American Heart Association (AHA) will present 20 late-breaking clinical trials and 20 clinical science-special reports at its scientific sessions in Dallas. The conference runs Nov. 16-20.

Here is the schedule for late-breaking trials:

Sunday, Nov. 17

  • Nitrites in Acute Myocardial Infarction
  • Blood Pressure Reduction Among Acute Ischemic Stroke Patients: A Randomized Controlled Clinical Trial
  • Randomized Clinical Trial of Pre-hospital Induction of Mild Hypothermia in Out-of-Hospital Cardiac Arrest Patients Using a Rapid Infusion of 4oC Normal Saline
  • Target Temperature Management 33°C versus 36°C after Out-of-hospital Cardiac Arrest, a Randomized, Parallel Group, Assessor Blinded Clinical Trial

Monday, Nov. 18

  • Promotion of Cardiovascular Health in Preschool Children: 36-month Cohort Follow-up
  • Randomized Trial of Social Network Lifestyle Intervention for Obesity: MICROCLINIC Intervention Results and 16-Month Follow-up
  • Multifaceted Intervention to Improve Medication Adherence and Secondary Prevention Measures (Medication Study) After Acute Coronary Syndrome Hospital Discharge
  • China Rural Health Initiative - Sodium Reduction Study: the Effects of a Community-Based Sodium Reduction Program on 24hr Urinary Sodium and Blood Pressure in Rural China
  • Atrial Antitachycardia Pacing and Managed Ventricular Pacing Reduce the Endpoint Composed by Death, Cardiovascular Hospitalizations and Permanent Atrial Fibrillation Compared to Conventional Dual Chamber Pacing in Bradycardia Patients: Results of the Minerva Randomized Study
  • Renal Optimization Strategies Evaluation in Acute Heart Failure (ROSE AHF) Trial
  • Severe Ischemic Mitral Regurgitation: Is it Better to Repair or Replace the Valve?
  • Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT)
  • One Year Mortality in STEMI Patients Randomized to Primary PCI or a Pharmaco-invasive Strategy. The Stream 1 Year Follow-up
  • Secretory Phospholipase A2 Inhibition with Varespladib and Cardiovascular Events in Patients with an Acute Coronary Syndrome: Results of the VISTA-16 Study
  • Randomized Comparison of Endovascular Revascularization Plus Supervised Exercise Therapy Versus Supervised Exercise Therapy Only in Patients With Peripheral Artery Disease and Intermittent Claudication: Results of the Endovascular Revascularization and Supervised Exercise (ERASE) Trial
  • A Randomized Multicenter Clinical Trial of Renal Artery Stenting in Preventing Cardiovascular and Renal Events: Results of the CORAL Study

Tuesday, Nov. 19

  • RADAR-AF Trial. A Randomized Multicenter Comparison of Radiofrequency Catheter Ablation of Drivers versus Circumferential Pulmonary Vein Isolation in Patients with Atrial Fibrillation
  • A Randomized Trial Comparing Genotype-Guided Dosing of Warfarin to Standard Dosing: The EU Pharmacogenetics of Anticoagulant Therapy (EU-PACT) Warfarin Study
  • The Clarification of Optimal Anticoagulation through Genetics (COAG) Trial
  • ENGAGE AF-TIMI 48 Primary Results

Here is the schedule for the clinical science/special reports:

Monday, Nov. 18

  • State of the Art: Cardiac Stem Cell Therapeutics from the Outside, Looking In
  • Mechanisms of Bone Marrow Derived Cell Therapy in Ischemic Cardiomyopathy with Left Ventricular Assist Device (LVAD) Bridge to Transplant
  • Assessment of Safety and Efficacy of Autologous Mesenchymal Stem Cells and Whole Bone Marrow in Patients with Ischemic Cardiomyopathy: The TAC-HFT Trial
  • Intramyocardial Injection of Allogeneic Mesenchymal Precursor Cells in Left Ventricular Assist Device Patients
  • The NHLBI TIME Trial: One-Year Results
  • Safety And Efficacy Of Sitagliptin Plus Granulocyte-colony Stimulating Factor In Patients Suffering From Acute Myocardial Infarction - Sitagrami Trial
  • Effect of Progenitor Cell Mobilization with Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) in Patients with Peripheral Artery Disease and Claudication; GPAD-II: A Phase II Randomized Study

Tuesday, Nov. 19

  • Outcome Impact of Coronary Revascularization Strategy - Reclassification With Fractional Flow Reserve (FFR) at time of diagnostic angiography: Insights from a Large French Multicenter FFR Registry (R3F)
  • CPT1A Methylation is a Novel Epigenetic Marker of Cardiovascular Risk
  • Ten-Year Incidence Rates of Major Cardiovascular Events in 697,690 Immigrants to Ontario, Canada, by Ethnic Group and Country of Birth
  • China Rural Health Initiative - Primary Care Provider Study: A Large Cluster-Randomized Controlled Trial of High Cardiovascular Risk Management in Rural China
  • Does Aspirin Intake at Bedtime Decrease Blood Pressure and Morning Peak of Platelet Reactivity?: A Randomized Cross-over Trial
  • Daylight: Vitamin D Therapy in Individuals at High Risk of Hypertension
  • Effect of Angiotensin II Type I Receptor Blockade on Carotid Artery Atherosclerosis: A Randomized Trial Comparing Valsartan and Placebo (EFFERVESCENT)
  • Randomized Comparison of the Safety, Tolerability, and Efficacy of Long-term Administration of AMG 145 versus Standard of Care in 1104 Patients: 52-week Results from the OSLER Study

Wednesday, Nov. 20

  • The Incidence of Kidney Injury for Patients Treated with Intensive versus Less Potent Statin Therapy after an Acute Coronary Syndrome
  • First-in-Man Clinical Evaluation of a Novel Tissue Engineered Vascular Graft
  • Dedicated ICD Programming Reduces the Number of Inappropriate Therapies in a Real World Primary Prevention ICD Population: The DECREASE – Trial
  • A Multicenter, Randomized Study Assessing the Efficacy of Left Ventricular Augmentation with Algisyl-LVR in the Treatment of Advanced Heart Failure Patients with Ischemic and Non-ischemic Cardiomyopathy: Interim Results of the AUGMENT-HF Study
Candace Stuart, Contributor

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Philips introduced a new CT system at ECR aimed at the rapidly growing cardiac CT market, incorporating numerous AI features to optimize workflow and image quality.

Trimed Popup
Trimed Popup